drugset / Trial / NCT02227797

MT2013-37R: Voriconazole Monitoring in Pediatric Stem Cell Transplant Patients

NCT02227797

Phase 1 Completed 66 enrolled Masonic Cancer Center, University of Minnesota
NaSingle-groupOpen-labelTreatment

Summary

The primary purpose of this study is to identify the optimal dose of voriconazole, an anti-fungal drug often used in people undergoing stem cell transplant. An optimal dose level is one level that provides a good blood level (concentration) of voriconazole without too much toxicity.

Timeline

Start
2015-01-19
Primary completion
2017-09-08
Completion
2019-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Voriconazole Small molecule 6 mg/kg Intravenous
Subject Voriconazole Small molecule 12 mg/kg Intravenous